Assessing Tolerability of Avonex Intramuscular Injections

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate patients' views when injecting Avonex intramuscularly.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saint Francis Care
• Collaborator: Biogen
• Treatments: Interferon beta-1a; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Between 18 - 65 years of age;

• Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis;

• Currently being treated with Avonex® for at least 90 days;

• Using 25 gauge needles for injection of Avonex® for at least 90 days;

• Willing and able to complete study questionnaires; and

• Provided informed consent to participate in this study

Exclusion Criteria:

• Diagnosis of Progressive Multiple Sclerosis;

• History of recent illness or infection;

• History of allergic reaction to Avonex®;

• Any prior usage of a 30 gauge needle for administration of Avonex®;

• Concurrent treatment with other immunomodulating therapies;

• Pregnant or planning on becoming pregnant;

• Nursing mothers; and

• Unable to complete the requirements of the study